NCT04640246

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

A Phase 1/2 Multi-Center Dose-Escalation Study of the Safety, Tolerability and Early Efficacy of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Taiga Biotechnologies, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a study of treatment with TBX-3400 in subjects with solid malignant tumors that are resistant or refractory to standard therapies. The subject's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity. The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response to the tumor.

Conditions

• Cancer
• Tumor, Solid
• Refractory Cancer

Interventions

Type	Name	Description
BIOLOGICAL	TBX-3400	Autologous transfusion

Timeline

• Start date: 2021-01-25
• Primary completion: 2023-01-01
• Completion: 2023-04-01
• First posted: 2020-11-23
• Last updated: 2022-02-02

Locations

2 sites across 2 countries: United States, Israel

Regulatory

• FDA-regulated drug study